Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.77 |
| ▸ | RAB9A | P51151 | 9/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610862 | 0.89 | CYP1A2 (0.72) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL107421 | 0.87 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL179084 | 0.87 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12611073 | 0.86 | CYP1A2 (0.63) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27666186 | 0.85 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1742667 | 0.84 | CYP1A2 (0.81) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1383868 | 0.84 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6993043 | 0.84 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12010919 | 0.83 | RAB9A (0.84) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL179080 | 0.82 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0799209-B1 | SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2003-08-06 | — | — | EP | claimed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| EP-1581467-B1 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2583958-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Institute of Technology (MIT) (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2013006408-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012127012-A1 | BIPHENYL TRICYCLIC QUINAZOLINE COMPOUNDS | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2012-09-27 | — | — | WO | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008113851-A2 | NOVEL C11 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1581467-A4 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1027309-A4 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA ARTHUR M (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1032262-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CYTOCHROME P450 IN PLANTS | NONOMURA, Arthur M. (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-1027309-A1 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA, Arthur M. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6020288-A | PLANT GROWTH AGENT | NONOMURA ARTHUR M (US) | 2000-02-01 | — | — | US | disclosed |
| US-5958104-A | APPLYING ALKYL GLUCOSIDE | NONOMURA ARTHUR M (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999012868-A1 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA ARTHUR M (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999012417-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CYTOCHROME P450 IN PLANTS | NONOMURA ARTHUR M (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | NPC1 1422/4885RAB9A 1020/4885SMN1; SMN2 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.